The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
A truncated form of human glucose-dependent insulinotropic polypeptide (GIP), GIP(3–30)NH2, was recently identified as an antagonist of the human GIP receptor. This study examined the ability of GIP(3–30)NH2 to antagonize the physiological actions of GIP in glucose metabolism, subcutaneous abdominal adipose tissue blood flow (ATBF), and lipid metabolism in humans. Eight lean subjects were studied by measuring arteriovenous concentrations of metabolites and ATBF on three different occasions during hyperglycemic-hyperinsulinemic clamps with concomitant infusions of GIP, GIP(3–30)NH2, or both GIP and GIP(3–30)NH2. During infusion of GIP(3–30)NH2 alone and in combination with GIP, insulin levels and the total glucose amount infused to maintain the clamp were lower than during GIP alone. In addition, ATBF remained constant during the antagonist and increased only slightly in combination with GIP, whereas it increased fivefold during GIP alone. Adipose tissue triacylglyceride (TAG) and glucose uptake decreased, and the free fatty acid/glycerol ratio increased during the antagonist alone and in combination with GIP. The changes in glucose infusion rates and plasma insulin levels demonstrate an inhibitory effect of the antagonist on the incretin effect of GIP. In addition, the antagonist inhibited GIP-induced increase in ATBF and decreased the adipose tissue TAG uptake, indicating that GIP also plays a crucial role in lipid metabolism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Previous in vitro and animal studies have shown that GIP may play a role in obesity and have suggested that GIP receptor may represent a target for the prevention and treatment of obesity (29,30).”
Self-citationAdipose tissue as a buffer for daily lipid flux
Frayn, K. (2002) · Diabetologia · doi:10.1007/s00125-002-0873-y · Cited by 752
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Self-citationFrayn, K. N., Shadid, S., Hamlani, R., Humphreys, S. M., Clark, M. L., Fielding, B. A., Boland, O., & Coppack, S. W. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.266.3.e308 · Cited by 188
Incretin Hormone and Insulin Responses to Oral Versus Intravenous Lipid Administration in Humans
Lindgren, O., Carr, R. D., Deacon, C. F., Holst, J. J., Pacini, G., Mari, A., & Ahrén, B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0266 · Cited by 188
Self-citationAsmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J. J., & Bülow, J. (2010) · Diabetes · doi:10.2337/db10-0098 · Cited by 184 · cited 4×
“We have previously demonstrated that GIP infusions in the presence of elevated insulin concentrations increased ATBF and stimulated triacylglyceride (TAG) deposition in adipose tissue in lean humans (1), suggesting that GIP together with insulin are controllers of postprandial fat deposition.”
BackgroundMethodResultInfluentialSelf-citationRegulation of human subcutaneous adipose tissue blood flow
Frayn, K. N., & Karpe, F. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.200 · Cited by 173
Summers, L. K. M., Samra, J. S., Humphreys, S. M., Morris, R. J., & Frayn, K. N. (1996) · Clinical Science · doi:10.1042/cs0910679 · Cited by 167
Tseng, C. C., Kieffer, T. J., Jarboe, L. A., Usdin, T. B., & Wolfe, M. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119060 · Cited by 151
Sparre‐Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & Rosenkilde, M. M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13323 · Cited by 114
Self-citation
Cited by
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Zhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
The incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
Self-citationBeyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“GIP acutely increases abdominal adipose tissue blood flow and enhances adipose tissue triglyceride clearance in humans studied under hyperinsulinaemic–hyperglycaemic clamp conditions, designed to mimic post-prandial physiology 42 .”
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
“Employment of GIPR signaling, specifically the direction of this manipulation, as a strategy to improve body weight remains a contentious subject of intense scientific investigation [22,32,33].”
BackgroundUrva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02033-5 · Cited by 202
Brown Adipose Tissue—A Translational Perspective
Carpentier, A. C., Blondin, D. P., Haman, F., & Richard, D. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac015 · Cited by 198
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
“In this study, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes in glucose and glucoregulatory hormones using the novel GIP receptor antagonist GIP(3-30)NH2 and the well-established GLP-1 receptor antagonist exendin(9-39)NH2.”
BackgroundMethodInfluentialSelf-citationWilson, J. M., Nikooienejad, A., Robins, D. A., Roell, W. C., Riesmeyer, J. S., Haupt, A., Duffin, K. L., Taskinen, M., & Ruotolo, G. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14174 · Cited by 164
Mayendraraj, A., Rosenkilde, M. M., & Gasbjerg, L. S. (2022) · Peptides · doi:10.1016/j.peptides.2022.170749 · Cited by 154
Self-citationTargeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Killion, E. A., Chen, M., Falsey, J. R., Sivits, G., Hager, T., Atangan, L., Helmering, J., Lee, J., Li, H., Wu, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18751-8 · Cited by 151
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
“Studies utilizing GIP(3e30) have been conducted in human subjects to test the role of GIP i) as a glucoincretin [73e75], ii) in adipose tissue metabolism [76], iii) in bone metabolism [77,78], and iv) in the regulation of energy expenditure and feeding behavior during a meal [75].”
BackgroundGastrointestinal hormones and regulation of gastric emptying
Camilleri, M. (2019) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000448 · Cited by 129
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Clemmensen, C., Finan, B., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Hofmann, S. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0118-x · Cited by 134
The Role of Incretins on Insulin Function and Glucose Homeostasis
Holst, J. J., Gasbjerg, L. S., & Rosenkilde, M. M. (2021) · Endocrinology · doi:10.1210/endocr/bqab065 · Cited by 124
Self-citationEvaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
Self-citationIncretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Boer, G. A., & Holst, J. J. (2020) · Biology · doi:10.3390/biology9120473 · Cited by 153
Self-citationSchiellerup, S. P., Skov‐Jeppesen, K., Windeløv, J. A., Svane, M. S., Holst, J. J., Hartmann, B., & ROSENKILDE, M. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00075 · Cited by 116
“PTH-analog (1-84) Natpara Hormone replacement therapy—long term action”
Self-citationGasbjerg, L. S., Christensen, M., Hartmann, B., Lanng, A. R., Sparre‐Ulrich, A. H., Gabe, M. B. N., Dela, F., Vilsbøll, T., Holst, J. J., ROSENKILDE, M. M., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4447-4 · Cited by 103
“Other effects of GIP(3-30)NH2 GIP(3-30)NH2 is the first GIP receptor antagonist used in humans, and in a subsequent study we have shown that the antagonist also inhibits triacylglycerol uptake in adipose tissue [48].”
BackgroundSelf-citationUssher, J. R., Campbell, J. E., Mulvihill, E. E., Baggio, L. L., Bates, H. E., McLean, B. A., Gopal, K., Capozzi, M. E., Yusta, B., Cao, X., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.003 · Cited by 107
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 112
Self-citationCarpentier, A. C. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00620.2020 · Cited by 108
Fothergill, L. J., & Furness, J. B. (2018) · Histochemistry and Cell Biology · doi:10.1007/s00418-018-1746-x · Cited by 93
“2018), GIP promotes the uptake of triacylglyceride in adipose tissue (Asmar et al. 2017), and PYY inhibits lipolysis (Castan et al.”
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
Leveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 83
Thondam, S. K., Cuthbertson, D. J., & Wilding, J. P. H. (2020) · Peptides · doi:10.1016/j.peptides.2019.170208 · Cited by 77
High glycemic index metabolic damage – a pivotal role of GIP and GLP-1
Pfeiffer, A. F. H., & Keyhani-Nejad, F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.03.003 · Cited by 74
“In humans, circulating levels of GIP are inversely correlated with insulin sensitivity [33] and a GIP antagonist improves insulin sensitivity when co-infused with GIP [45].”
Skov-Jeppesen, K., Svane, M. S., Martinussen, C., Gabe, M. B. N., Gasbjerg, L. S., Veedfald, S., Bojsen-Møller, K. N., Madsbad, S., Holst, J. J., Rosenkilde, M. M., et al. (2019) · Bone · doi:10.1016/j.bone.2019.05.014 · Cited by 75
Self-citationTheilade, S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14270 · Cited by 82
GIP and GLP-1 receptor antagonism during a meal in healthy individuals
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz175 · Cited by 68
Self-citationGlucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Self-citationThe role of endogenous GIP and GLP-1 in postprandial bone homeostasis
Helsted, M. M., Gasbjerg, L. S., Lanng, A. R., Bergmann, N. C., Stensen, S., Hartmann, B., Christensen, M., Holst, J. J., Vilsbøll, T., ROSENKILDE, M. M., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115553 · Cited by 64
Self-citationXie, C., Jones, K. L., Rayner, C. K., & Wu, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090790 · Cited by 67
“In line with these findings, the antagonism of the GIP receptor is associated with reduced blood flow and triglyceride deposition in adipose tissue in healthy subjects [95].”
ResultDiscovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
Yang, B., Gelfanov, V. M., El, K., Chen, A., Rohlfs, R., DuBois, B., Kruse Hansen, A. M., Perez-Tilve, D., Knerr, P. J., D'Alessio, D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101638 · Cited by 55
Holst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
Self-citationGutgesell, R. M., Khalil, A., Liśkiewicz, A., Maity‐Kumar, G., Novikoff, A., Grandl, G., Liśkiewicz, D., Coupland, C., Karaoglu, E., Akindehin, S., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01294-x · Cited by 62
“…the periphery and the brain, the PNS is well positioned to control energy metabolism, not only by modulating glycaemia via regulation of sympathetic outflow to the skeletal muscle 32 , but also by promoting GIP-induced vasodilation in the mesenteric vasculature, including the adipose tissue 33,34 .”
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Roh, E., & Choi, K. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043384 · Cited by 66
“GIP also plays an important role in lipid metabolism by promoting lipid storage by increasing adipose tissue blood flow and triglyceride uptake [71].”
BackgroundSamms, R. J., Sloop, K. W., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2021) · Diabetes · doi:10.2337/dbi21-0002 · Cited by 49
“Consistent with this, blockade of GIPR impairs postprandial lipid clearance in rodents and man (28,29).”
BackgroundKnerr, P. J., Mowery, S. A., Finan, B., Perez-Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2020) · Peptides · doi:10.1016/j.peptides.2019.170225 · Cited by 49
Smith, C., Patterson-Cross, R., Woodward, O., Lewis, J., Chiarugi, D., Merkle, F., Gribble, F., Reimann, F., & Adriaenssens, A. (2022) · Appetite · doi:10.1016/j.appet.2022.106022 · Cited by 47
Sohn, M., Jung, H., Lee, W. S., Kim, T. H., & Lim, S. K. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0370 · Cited by 56
“In healthy adults, inhibition of GIP by GIP(3–30)NH2 induced lipid metabolism by reducing adipocyte TG levels [36].”
GIP and the gut-bone axis – Physiological, pathophysiological and potential therapeutic implications
Stensen, S., Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Christensen, M., & Knop, F. K. (2019) · Peptides · doi:10.1016/j.peptides.2019.170197 · Cited by 49
Self-citationGasbjerg, L. S., Rosenkilde, M. M., Meier, J. J., Holst, J. J., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15216 · Cited by 41
“45 The mesenteric blood flow is also increased during GIP administration 46 and this might be connected to the increase in heart rate observed following GIP administration.”
BackgroundSelf-citationGlucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
“Consistent with observations during the postprandial state, Ding et al (84) and Asmar et al (95) reported that GIP enhanced portal venous and subcutaneous adipose tissue blood flow, respectively.”
GIP’s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3–30)NH2
Gasbjerg, L. S., Hartmann, B., Christensen, M. B., Lanng, A. R., Vilsbøll, T., Jørgensen, N. R., Holst, J. J., Rosenkilde, M. M., & Knop, F. K. (2020) · Bone · doi:10.1016/j.bone.2019.115079 · Cited by 40
Self-citationBoer, G. A., Keenan, S. N., Miotto, P. M., Holst, J. J., & Watt, M. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00646.2020 · Cited by 38
Self-citationGIP-induced vasodilation in human adipose tissue involves capillary recruitment
Asmar, M., Asmar, A., Simonsen, L., Dela, F., Holst, J. J., & Bülow, J. (2019) · Endocrine Connections · doi:10.1530/ec-19-0144 · Cited by 37
Self-citationKaneko, S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.10 · Cited by 58
“Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry.”
BackgroundMethodNovel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Baldassano, S., Gasbjerg, L. S., Kizilkaya, H. S., ROSENKILDE, M. M., Holst, J. J., & Hartmann, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00492 · Cited by 34
“It increases adipose tissue blood flow and stimulates fat deposition (69, 70) and the GIPR antagonist, human GIP(3-30)NH2, decreases adipose tissue triacylglyceride uptake and increases the free fatty acid/glycerol ratio (14, 55).”
BackgroundSelf-citationRecent advances of GIP and future horizons
Holst, J. J., & Rosenkilde, M. M. (2020) · Peptides · doi:10.1016/j.peptides.2019.170230 · Cited by 33
Self-citationHeimbürger, S. M. N., Hoe, B., Nielsen, C. N., Bergmann, N. C., Skov‐Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Overgaard, A. J., Størling, J., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac542 · Cited by 34
Self-citationLiu, H., Xiao, H., Lin, S., Zhou, H., Cheng, Y., Xie, B., & Xu, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1372399 · Cited by 40
Carreau, A., Noll, C., Blondin, D. P., Frisch, F., Nadeau, M., Pelletier, M., Phoenix, S., Cunnane, S. C., Guérin, B., Turcotte, É. E., et al. (2020) · Diabetes · doi:10.2337/db19-0773 · Cited by 32
“Increased postprandial GIP after SG may also contribute to adipose tissue fatty acid uptake (31).”
BackgroundYuan, L., Zhang, J., Guo, J., Hölscher, C., Yang, J., Wu, M., Wang, Z.-J., Cai, H.-Y., Han, L., Shi, H., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201262 · Cited by 30
“And GIP(3-30)NH2, a reversible competitive antagonist of GIPR in rodents [51] and as well as humans [52, 53], effectively antagonized GIP-mediated G protein-signaling as well as pancreatic hormone release.”
Gasbjerg, L. S., Rasmussen, R. S., Dragan, A., Lindquist, P., Melchiorsen, J. U., Stępniewski, T. M., Schiellerup, S. P., Tordrup, E. K., Gadgaard, S., Kizilkaya, H. S., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16478 · Cited by 34
“More-over, GIP administration to healthy individuals may induce glucagon secretion during euglycaemia and hypoglycaemia (Christensen et al., 2011) and stimulate the deposition of triglycerides in subcutaneous adipose tissue (Asmar et al., 2017).”
Self-citationIrwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27
Gribble, F. M., Reimann, F., & Roberts, G. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00002-5 · Cited by 30
The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
Kagdi, S., Lyons, S. A., & Beaudry, J. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0361 · Cited by 33
Gasbjerg, L. S., Bari, E. J., Stensen, S., Hoe, B., Lanng, A. R., Mathiesen, D. S., Christensen, M. B., Hartmann, B., Holst, J. J., Rosenkilde, M. M., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14186 · Cited by 24
Self-citationInvestigating GIPR (ant)agonism: A structural analysis of GIP and its receptor
Smit, F. X., van der Velden, W. J. C., Kizilkaya, H. S., Nørskov, A., Lückmann, M., Hansen, T. N., Sparre-Ulrich, A. H., Qvotrup, K., Frimurer, T. M., & Rosenkilde, M. M. (2021) · Structure · doi:10.1016/j.str.2021.04.001 · Cited by 24
Self-citationSkov‐Jeppesen, K., Veedfald, S., Madsbad, S., Holst, J. J., ROSENKILDE, M. M., & Hartmann, B. (2021) · Bone · doi:10.1016/j.bone.2021.116065 · Cited by 24
Self-citationCombined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice
Ying, Z., van Eenige, R., Ge, X., van Marwijk, C., Lambooij, J. M., Guigas, B., Giera, M. A., de Boer, J. F., Coşkun, T., Qu, H., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104684 · Cited by 28
GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology
ROSENKILDE, M. M., Lindquist, P., Kizilkaya, H. S., & Gasbjerg, L. S. (2024) · Peptides · doi:10.1016/j.peptides.2024.171212 · Cited by 22
“For instance, in terms of ligand selectivity, the GIPR is more selective than the more promiscuous GLP-1 receptor and is only potently activated by GIP(1-42) and the C-terminally cleaved variant of this (GIP(1-30)NH 2 ) [36] while the GLP-1R can be rather potently activated by several endogenous…”
BackgroundInfluentialSelf-citationRabbani, N., & Thornalley, P. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111905 · Cited by 25
Abdrabou Abouelmagd, A., Abdelrehim, A. M., Bashir, M. N., Abdelsalam, F., Marey, A., Tanas, Y., Abuklish, D. M., & Belal, M. M. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2456441 · Cited by 25
Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease
Shang, R., & Rodrigues, B. B. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.13199 · Cited by 21
Mather, K. J., Mari, A., Weerakkody, G. J., Heise, T., DeVries, J. H., Urva, S., Coşkun, T., Miličević, Z., Haupt, A., & Thomas, M. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16159 · Cited by 24
Perry, R., Craig, S., Ng, M., Gault, V. A., Flatt, P. R., & Irwin, N. (2019) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551419875453 · Cited by 19
Beaudry, J. L., & Drucker, D. J. (2019) · Endocrinology · doi:10.1210/endocr/bqz029 · Cited by 24
“Notably, exendin(9-39), an antagonist of the canonical GLP-1R, did not attenuate the actions of GLP-1 on human adipocytes (59).”
BackgroundEffects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes
Skov‐Jeppesen, K., Christiansen, C. B., Hansen, L. S., Windeløv, J. A., Hedbäck, N., Gasbjerg, L. S., HINDSØ, M. G., Svane, M. S., Madsbad, S., Holst, J. J., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae022 · Cited by 22
Self-citationMorrow, N. M., Hanson, A. A., & Mulvihill, E. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.703966 · Cited by 19
“GIPR antagonist, GIP(3–30)NH2, and GIP co-infusion in lean individuals prevented a fivefold increase in adipose tissue blood flow induced by GIP infusion alone (Asmar et al., 2017).”
BackgroundPetrov, M. S. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1931118 · Cited by 18
Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans
Veedfald, S., Vedtofte, L., Skov‐Jeppesen, K., Deacon, C. F., Hartmann, B., Vilsbøll, T., Knop, F. K., Christensen, M., & Holst, J. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz097 · Cited by 17
Self-citationPhysiology and clinical applications of GIP
Yamane, S., Harada, N., & Inagaki, N. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej25-0087 · Cited by 16
“GIP (3–30)NH 2 significantly suppressed GIP-stimulated insulin secretion during a hyperglycemic clamp [119] and the GIP-induced increase in adipose tis‐ sue blood flow was almost completely abolished by GIP (3–30)NH 2 administration [120].”
ROSENKILDE, M. M., George, J. T., Véniant, M. M., & Holst, J. J. (2025) · Diabetes · doi:10.2337/dbi24-0027 · Cited by 19
Self-citationProtective Effects of Incretin Against Age-Related Diseases
Zhang, D., Ma, M., & Liu, Y. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191010145029 · Cited by 15
GIP(3-30)NH2 – a tool for the study of GIP physiology
Lynggaard, M. B., Gasbjerg, L. S., Christensen, M., & Knop, F. K. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.011 · Cited by 17
Self-citationHeimburger, S. M. N., Nielsen, C. N., Calanna, S., Holst, J. J., Vilsbøll, T., Knop, F. K., & Christensen, M. B. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14545 · Cited by 13
Self-citationDouros, J. D., Mowery, S. A., & Knerr, P. J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113812 · Cited by 12
“…GIP is secreted most potently in response to high lipid meals [16], while GIP infusion enhances adipose tissue blood flow in lean patients [17] and lipid deposition (e.g., reduced plasma non-essential fatty acids (NEFA), increased adipose triglycerides (TG)) in patients with obesity and…”
Rasmussen, R. S., Langberg, L. S., Østergaard, F., Nielsen, S. W., Vestergaard, M. B., Skov‐Jeppesen, K., Hartmann, B., Johannesen, H. H., Holst, J. J., Haddock, B., et al. (2025) · Diabetes · doi:10.2337/db25-0149 · Cited by 13
Self-citationPharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
Lee, E., Miedzybrodzka, E. L., Zhang, X., Hatano, R., Miyamoto, J., Kimura, I., Fujimoto, K., Uematsu, S., Rodríguez‐Cuenca, S., Vidal‐Puig, A., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184448 · Cited by 14
“Indeed, several GIP receptor antagonists are under development with the goal of reducing body weight in humans [9,10].”
BackgroundBoer, G. A., Hunt, J. E., Gabe, M. B. N., Windeløv, J. A., Sparre‐Ulrich, A. H., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15894 · Cited by 13
“The most potent antagonist of the truncated GIP variants, GIP(3-30) NH2 was shown to inhibit GIP receptor signalling in human adipocytes (Gabe et al., 2018) and to inhibit triglyceride deposition in subcutaneous adipose tissue in humans during in vivo infusions (Asmar et al., 2017).”
BackgroundSelf-citationCurrent Approaches in Diabetes Treatment and Other Strategies to Reach Normoglycemia
Sirhan, W., & Piran, R. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200716113813 · Cited by 13
The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection
Lindquist, P., Gasbjerg, L. S., Mokrosiński, J., Holst, J. J., Hauser, A. S., & ROSENKILDE, M. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.891586 · Cited by 11
Self-citationThe evolution of the therapeutic concept ‘GIP receptor antagonism’
Koefoed-Hansen, F., Helsted, M. M., Kizilkaya, H. S., Lund, A., ROSENKILDE, M. M., & Gasbjerg, L. S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1570603 · Cited by 9
Self-citationErfanian, S., Mir, H., Abdoli, A., & Roustazadeh, A. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01477-z · Cited by 10
Jensen, M., Gasbjerg, L. S., Skov‐Jeppesen, K., Jacobsen, J. C., Poulsen, S. S., Zhou, C., Jakubauskaite, R., Poulsen, F. R., Bonde, C., Albarazi, M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae583 · Cited by 8
Self-citationGaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 8
“In rodent and canine models, GIP infusion promotes lipid disposal and healthy expansion of WAT [74–76]; whereas, GIP inhibition increases circulating post-prandial triglyceride levels [77,78].”
Hemami, R. M., Shakarami, A., Ardekani, A. M., Aghaii, S., Makarem, D., Nikrad, N., Farhangi, M. A., & Abbasi, M. S. P. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01458-4 · Cited by 9
“Gluconeogen-esis, glycogenolysis, and lipolysis from adipose tissues can all be systemically regulated by these changes in the metabolic and hormonal milieu [46, 47].”
BackgroundZhang, T., Liu, S., He, S., Shi, L., & Ma, R. (2025) · ChemBioChem · doi:10.1002/cbic.202400962 · Cited by 10
Regulation of feeding and therapeutic application of bioactive peptides
Ueno, H., Zhang, W., & Nakazato, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108187 · Cited by 7
Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf779 · Cited by 6
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Bailey, C. J., & Flatt, P. R. (2024) · Peptides · doi:10.1016/j.peptides.2024.171168 · Cited by 6
Metadata
- Authors
- Asmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J.
- Affiliations
- Bispebjerg Hospital (DK)
- University of Copenhagen (DK)
- Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
- Corresponding author
- Asmar, Meena
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2017-06-30
- Volume
- 66
- Issue
- 9
- Pages
- 2363-2371
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2728467537
- Cited by
- 132
- References
- 32
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 14 · 2023: 8 · 2022: 16 · 2021: 14 · 2020: 14 · 2019: 22 · 2018: 10 · 2017: 2
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- European Foundation for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor antagonist, incretin effect, adipose tissue blood flow, adipose tissue glucose uptake, lipid metabolism, glucose metabolism, insulin secretion
- MeSH terms
- Adipose Tissue, Adult, Blood Glucose, Fatty Acids, Nonesterified, Gastric Inhibitory Polypeptide, Glucose, Glycerol, Humans, Male, Peptide Fragments, Receptors, Gastrointestinal Hormone, Triglycerides, Glucose Clamp Technique, Cross-Over Studies, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.